Indofarma Tbk - Asset Resilience Ratio
Indofarma Tbk (INAF) has an Asset Resilience Ratio of 16.37% as of September 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Indofarma Tbk (INAF) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2000–2022)
This chart shows how Indofarma Tbk's Asset Resilience Ratio has changed over time. See INAF net asset value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Indofarma Tbk's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Indofarma Tbk market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rp209.05 Billion | 14.02% |
| Short-term Investments | Rp35.00 Billion | 2.35% |
| Total Liquid Assets | Rp244.05 Billion | 16.37% |
Asset Resilience Insights
- Good Liquidity Position: Indofarma Tbk maintains a healthy 16.37% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Indofarma Tbk Industry Peers by Asset Resilience Ratio
Compare Indofarma Tbk's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Daihan Pharmaceutical Co.Ltd
KQ:023910 |
Drug Manufacturers - Specialty & Generic | 11.95% |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA |
Drug Manufacturers - Specialty & Generic | 16.92% |
|
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SHE:000999 |
Drug Manufacturers - Specialty & Generic | 5.22% |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538 |
Drug Manufacturers - Specialty & Generic | 2.69% |
|
Zhejiang Xianju Pharmaceutical Co Ltd
SHE:002332 |
Drug Manufacturers - Specialty & Generic | 6.02% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Hainan Honz Pharmaceutical Co
SHE:300086 |
Drug Manufacturers - Specialty & Generic | 0.27% |
|
Guangdong Lifestrong Pharmacy Co. Ltd.
SHE:301111 |
Drug Manufacturers - Specialty & Generic | 7.85% |
Annual Asset Resilience Ratio for Indofarma Tbk (2000–2022)
The table below shows the annual Asset Resilience Ratio data for Indofarma Tbk.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | 20.04% | Rp307.44 Billion ≈ $18.01 Million |
Rp1.53 Trillion ≈ $89.89 Million |
+1.29pp |
| 2021-12-31 | 18.76% | Rp377.34 Billion ≈ $22.11 Million |
Rp2.01 Trillion ≈ $117.89 Million |
+13.87pp |
| 2020-12-31 | 4.88% | Rp83.65 Billion ≈ $4.90 Million |
Rp1.71 Trillion ≈ $100.39 Million |
+5.86pp |
| 2019-12-31 | -0.98% | Rp-13.57 Billion ≈ $-795.26K |
Rp1.38 Trillion ≈ $81.09 Million |
-0.03pp |
| 2018-12-31 | -0.95% | Rp-13.76 Billion ≈ $-806.07K |
Rp1.44 Trillion ≈ $84.52 Million |
-0.04pp |
| 2017-12-31 | -0.91% | Rp-13.93 Billion ≈ $-816.30K |
Rp1.53 Trillion ≈ $89.64 Million |
+0.11pp |
| 2016-12-31 | -1.02% | Rp-14.11 Billion ≈ $-826.88K |
Rp1.38 Trillion ≈ $80.96 Million |
-0.09pp |
| 2015-12-31 | -0.93% | Rp-14.29 Billion ≈ $-837.45K |
Rp1.53 Trillion ≈ $89.87 Million |
-0.93pp |
| 2011-12-31 | 0.00% | Rp28.00 Million ≈ $1.64K |
Rp1.11 Trillion ≈ $65.33 Million |
0.00pp |
| 2010-12-31 | 0.00% | Rp30.50 Million ≈ $1.79K |
Rp733.96 Billion ≈ $43.01 Million |
+0.00pp |
| 2009-12-31 | 0.00% | Rp25.00 Million ≈ $1.46K |
Rp728.03 Billion ≈ $42.66 Million |
+0.00pp |
| 2008-12-31 | 0.00% | Rp25.00 Million ≈ $1.46K |
Rp965.81 Billion ≈ $56.59 Million |
-0.23pp |
| 2007-12-31 | 0.23% | Rp2.34 Billion ≈ $136.88K |
Rp1.01 Trillion ≈ $59.15 Million |
-0.99pp |
| 2006-12-31 | 1.22% | Rp8.39 Billion ≈ $491.33K |
Rp686.94 Billion ≈ $40.25 Million |
-0.72pp |
| 2005-12-31 | 1.94% | Rp10.08 Billion ≈ $590.68K |
Rp518.82 Billion ≈ $30.40 Million |
-5.71pp |
| 2004-12-31 | 7.65% | Rp40.08 Billion ≈ $2.35 Million |
Rp523.92 Billion ≈ $30.70 Million |
+3.17pp |
| 2003-12-31 | 4.48% | Rp28.50 Billion ≈ $1.67 Million |
Rp635.96 Billion ≈ $37.26 Million |
-0.51pp |
| 2002-12-31 | 4.99% | Rp40.44 Billion ≈ $2.37 Million |
Rp810.03 Billion ≈ $47.46 Million |
-1.40pp |
| 2001-12-31 | 6.39% | Rp51.89 Billion ≈ $3.04 Million |
Rp811.62 Billion ≈ $47.56 Million |
-3.24pp |
| 2000-12-31 | 9.63% | Rp51.85 Billion ≈ $3.04 Million |
Rp538.17 Billion ≈ $31.53 Million |
-- |
About Indofarma Tbk
PT Indofarma Tbk, together with its subsidiaries, manufactures and sells pharmaceutical products in Indonesia and internationally. The company offers laboratory, pharmaceutical, and health glass equipment; orthopedic and prosthetic equipment; medical and dental equipment; and reparation of Irradiation / X-ray, electromedical and electrotherapy equipment. It also trades in laboratory, pharmaceutic… Read more